The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
New targets and approaches in osteosarcoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
The Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,786
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S.-H. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 899
p53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
O'Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo Lechowicz, M., Savage, K. J., Shustov, A. R., Gisselbrecht, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9024 · Cited by 647
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6<2163::aid-cncr2820430602>3.0.co;2-s · Cited by 592
Nilsson, S., Franzén, L., Parker, C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D. C., Sokal, M., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70147-x · Cited by 496
Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma
Jaffe, N., Frei, E., Traggis, D., & Bishop, Y. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911902 · Cited by 483
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Bacci, G., Ferrari, S., Bertoni, F., Ruggieri, P., Picci, P., Longhi, A., Casadei, R., Fabbri, N., Forni, C., Versari, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4016 · Cited by 438
Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
Branstetter, D. G., Nelson, S. D., Manivel, J. C., Blay, J.-Y., Chawla, S., Thomas, D. M., Jun, S., & Jacobs, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0578 · Cited by 426
The Aurora kinase family in cell division and cancer
Vader, G., & Lens, S. M. A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.07.003 · Cited by 417
Goorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., & Link, M. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.165 · Cited by 395
MARCOVE, R. C., MIKÉ, V., HAJEK, J. V., LEVIN, A. G., & HUTTER, R. V. P. (1970) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-197052030-00001 · Cited by 361
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Fidler, I. J., Sone, S., Fogler, W. E., & Barnes, Z. L. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1680 · Cited by 324
Amputation and Adriamycin in Primary Osteosarcoma
Cortes, E. P., Holland, J. F., Wang, J. J., Sinks, L. F., Blom, J., Senn, H., Bank, A., & Glidewell, O. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911903 · Cited by 317
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Self-citationMeyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294
Self-citationFerracini, R., Renzo, M. F. D., Scotlandi, K., Baldini, N., Olivero, M., Lollini, P., Cremona, O., Campanacci, M., & Comoglio, P. M. (1995) · PubMed · Cited by 280
Recent advances in the chemotherapy of metastatic osteogenic sarcoma
Jaffe, N. (1972) · Cancer · doi:10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h · Cited by 273
Nilsson, S., Strang, P., Aksnes, A. K., Franzèn, L., Olivier, P., Pecking, A., Staffurth, J., Vasanthan, S., Andersson, C., & Bruland, Ø. S. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.023 · Cited by 247
Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., Blay, J.-Y., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 246
Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Self-citationPrimary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy
Rosen, G., Marcove, R. C., Huvos, A. G., Caparros, B. I., Lane, J. M., Nirenberg, A., Cacavio, A., & Groshen, S. (1983) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00625054 · Cited by 228
MacEwen, E. G., Kurzman, I. D., Rosenthal, R. C., Smith, B. W., Manley, P. A., Roush, J. K., & Howard, P. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.12.935 · Cited by 228
Maris, J. M., Morton, C. L., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Keir, S. T., Reynolds, C. P., Kang, M. H., Wu, J., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22430 · Cited by 226
Self-citationGoorin, A. M., Harris, M. B., Bernstein, M. L., Ferguson, W., Devidas, M., Siegal, G. P., Gebhardt, M. C., Schwartz, C. L., Link, M. P., & Grier, H. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.426 · Cited by 223
Bond, M., Bernstein, M. L., Pappo, A., Schultz, K. R., Krailo, M., Blaney, S. M., & Adamson, P. C. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21132 · Cited by 211
ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
Onda, M., Matsuda, S., Higaki, S., Iijima, T., Fukushima, J.-I., Yokokura, A., Kojima, T., Horiuchi, H., Kurokawa, T., & Yamamoto, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960101)77:1<71::aid-cncr13>3.0.co;2-5 · Cited by 201
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Self-citationCortes, E. P. (1972) · JAMA · doi:10.1001/jama.1972.03200230020005 · Cited by 183
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
Meyers, P. A., Healey, J. H., Chou, A. J., Wexler, L. H., Merola, P. R., Morris, C. D., Laquaglia, M. P., Kellick, M. G., Abramson, S. J., & Gorlick, R. (2011) · Cancer · doi:10.1002/cncr.25744 · Cited by 178
Self-citationNeoadjuvant chemotherapy for osteosarcoma of the extremity
Bacci, G., Briccoli, A., Ferrari, S., Longhi, A., Mercuri, M., Capanna, R., Donati, D., Lari, S., Forni, C., & DePaolis, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00229-5 · Cited by 174
Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature
Bridge, J. A., Nelson, M., McComb, E., McGuire, M. H., Rosenthal, H., Vergara, G., Maale, G. E., Spanier, S., & Neff, J. R. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00306-8 · Cited by 171
Le Deley, M.-C., Guinebretière, J.-M., Gentet, J.-C., Pacquement, H., Pichon, F., Marec-Bérard, P., Entz-Werlé, N., Schmitt, C., Brugières, L., Vanel, D., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.023 · Cited by 162
Gucalp, A., Sparano, J. A., Caravelli, J., Santamauro, J., Patil, S., Abbruzzi, A., Pellegrino, C., Bromberg, J., Dang, C., Theodoulou, M., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.021 · Cited by 159
Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Reynolds, C. P., Maris, J. M., Keir, S. T., Billups, C. A., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21296 · Cited by 158
Self-citationPemetrexed: A multitargeted antifolate
Rollins, K. D., & Lindley, C. M. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.09.010 · Cited by 147
Winkler, K., Bielack, S., Delling, G., Salzer-Kuntschik, M., Kotz, R. I., Greenshaw, C., Jürgens, H., Ritter, J., Kusnierz-Glaz, C. R., Erttmann, R., et al. (1990) · Cancer · Cited by 146
Bacci, G., Mercuri, M., Longhi, A., Ferrari, S., Bertoni, F., Versari, M., & Picci, P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.036 · Cited by 138
Doxorubicin in disseminated osteosarcoma
Cores, E. P. (1972) · JAMA · doi:10.1001/jama.221.10.1132 · Cited by 138
MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas
Patanè, S., Avnet, S., Coltella, N., Costa, B., Sponza, S., Olivero, M., Vigna, E., Naldini, L., Baldini, N., Ferracini, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4422 · Cited by 132
Anderson, P. M., Markovic, S. N., Sloan, J. A., Clawson, M. L., Wylam, M. E., Arndt, C. A. S., Smithson, W. A., Burch, P. A., Gornet, M. E., & Rahman, E. (1999) · PubMed · Cited by 118
Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma
Kleinerman, E. S., Gano, J. B., Johnston, D. A., Benjamin, R. S., & Jaffe, N. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199504000-00001 · Cited by 116
Kubo, T., Piperdi, S., Rosenblum, J., Antonescu, C. R., Chen, W., Kim, H., Huvos, A. G., Sowers, R. S., Meyers, P. A., Healey, J. H., et al. (2008) · Cancer · doi:10.1002/cncr.23437 · Cited by 112
Self-citationHarris, M. B., Cantor, A. B., Goorin, A. M., Shochat, S. J., Ayala, A. G., Ferguson, W. S., Holbrook, T., & Link, M. P. (1995) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950240205 · Cited by 110
cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.
Ochs, J. J., Freeman, A. I., Douglass, H. O., Ds, H., Mindell, E. R., & Lf, S. (1978) · PubMed · Cited by 108
Pakos, E. E., & Ioannidis, J. P. A. (2003) · Cancer · doi:10.1002/cncr.11546 · Cited by 106
Cell surface receptor expression patterns in osteosarcoma
Hassan, S. E., Bekarev, M., Kim, M., Lin, J., Piperdi, S., Gorlick, R. G., & Geller, D. S. (2011) · Cancer · doi:10.1002/cncr.26339 · Cited by 99
Self-citationFrontline treatment of localized osteosarcoma without methotrexate
Daw, N. C., Neel, M. D., Rao, B. N., Billups, C. A., Wu, J., Jenkins, J. J., Quintana, J. A., Luchtman‐Jones, L., Milena Villarroel, C., & Santana, V. M. (2011) · Cancer · doi:10.1002/cncr.25715 · Cited by 99
Zoledronic acid inhibits osteosarcoma growth in an orthotopic model
Dass, C. R., & Choong, P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0546 · Cited by 91
High-dose ifosfamide in advanced osteosarcoma.
Marti, C., Kröner, P. T., Remagen, W., Berchtold, W., Cserhati, M., & Varini, M. (1985) · PubMed · Cited by 89
Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.
Thomas, D. G., Giordano, T. J., Sanders, D., Biermann, J. S., & Baker, L. H. (2002) · PubMed · Cited by 89
Kilpatrick, S. E., Geisinger, K. R., King, T. S., Sciarrotta, J., Ward, W. G., Gold, S., & Bos, G. D. (2001) · Modern Pathology · doi:10.1038/modpathol.3880474 · Cited by 88
Arndt, C. A. S., Koshkina, N., Inwards, C. Y., Hawkins, D. S., Krailo, M., Villaluna, D., Anderson, P. M., Goorin, A. M., Blakely, M. L., Bernstein, M. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0662 · Cited by 87
Gentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00439-x · Cited by 86
RANKL expression is related to treatment outcome of patients with localized, high‐grade osteosarcoma
Lee, J. A., Jung, J. S., Kim, D. H., Lim, J. S., Kim, M. S., Kong, C., Song, W. S., Cho, W. H., Jeon, D., Lee, S., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22720 · Cited by 85
Wang, Y., Han, X., Qiu, Y., Xiong, J., Yu, Y., Wang, B., Zhu, Z., Qian, B., Chen, Y., Wang, S., et al. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22077 · Cited by 83
Kolb, E. A., Kamara, D., Zhang, W., Lin, J., Hingorani, P., Baker, L. H., Houghton, P. J., & Gorlick, R. G. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22479 · Cited by 83
Self-citationCorrelation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
Abdeen, A. R., Chou, A. J., Healey, J. H., Khanna, C., Osborne, T. S., Hewitt, S. M., Kim, M., Wang, D., Moody, K. M., & Gorlick, R. G. (2009) · Cancer · doi:10.1002/cncr.24562 · Cited by 80
Self-citationSavage, S. A., Woodson, K. G., Walk, E. L., Modi, W. S., Liao, J. S., Douglass, C. W., Hoover, R. N., Chanock, S. J., & The National Osteosarcoma Etiology Study Group (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0214 · Cited by 80
Goldsby, R. E., Fan, T. M., Villaluna, D., Wagner, L. M., Isakoff, M. S., Meyer, J. S., Randall, R. L., Lee, S. C. L., Kim, G., Bernstein, M. L., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.018 · Cited by 77
Self-citationFury, M. G., Baxi, S. S., Shen, R., Kelly, K. W., Lipson, B. L., Carlson, D. L., Stambuk, H. E., Haque, S. S., & Pfister, D. G. (2011) · PubMed · Cited by 75
Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity
Bacci, G., Forni, C., Ferrari, S., Longhi, A., Bertoni, F., Mercuri, M., Donati, D. M., Capanna, R., Bernini, G., Briccoli, A., et al. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200311000-00006 · Cited by 70
Hingorani, P., Zhang, W., Gorlick, R. G., & Kolb, E. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1657 · Cited by 70
Self-citationSynthesis and antitumor activity of 10-propargyl-10-deazaaminopterin
DeGraw, J. I., Colwell, W. T., Piper, J. R., & Sirotnak, F. M. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00067a020 · Cited by 69
Beristain, A. G., Narala, S., Grappa, M. A. D., & Khokha, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.094029 · Cited by 67
Entz‐Werlé, N., Lavaux, T., Metzger, N., Stoetzel, C., Lasthaus, C., Marec‐Bérard, P., Kalita, C., Brugières, L., Pacquement, H., Schmitt, C., et al. (2007) · Neoplasia · doi:10.1593/neo.07367 · Cited by 60
Alendronate regulates cell invasion and MMP‐2 secretion in human osteosarcoma cell lines
Cheng, Y. Y., Huang, L., Lee, K., Li, K., & Kumta, S. M. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20019 · Cited by 60
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms053 · Cited by 58
Smeland, S., Bruland, Ø. S., Hjorth, L., Brosjö, O., Bjerkehagen, B., Österlundh, G., Jakobson, Å. M., Hall, K. S., Monge, O. R., Björk, O., et al. (2011) · Acta Orthopaedica · doi:10.3109/17453674.2011.566141 · Cited by 57
MacKay, H. J., Au, H., McWhirter, E., Alcindor, T., Jarvi, A., MacAlpine, K., Wang, L. E., Wright, J. J., & Oza, A. M. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9650-4 · Cited by 56
Adjuvant Interferon Treatment of Human Osteosarcoma
Strander, H. A., Adamson, U. K. C., Aparisi, T., Broström, L., Cantell, K., Einhorn, S., Hall, K. E., Ingimarsson, S., Nilsonne, U., & Söderberg, G. (1979) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-81332-0_7 · Cited by 52
Kolb, E. A., Gorlick, R. G., Maris, J. M., Keir, S. T., Morton, C. L., Wu, J., Wozniak, A. W., Smith, M. A., & Houghton, P. J. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23157 · Cited by 52
Self-citationSampson, E. R., Martin, B., Morris, A. E., Xie, C. L., Schwarz, E. M., O’Keefe, R. J., & Rosier, R. N. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.336 · Cited by 51
Bagatell, R., Herzog, C. E., Trippett, T. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1731 · Cited by 49
Krug, L. M., Azzoli, C. G., Kris, M. G., Miller, V. A., Khokhar, N. Z., Tong, W. P., Ginsberg, M. S., Venkatraman, E. S., Tyson, L. B., Pizzo, B., et al. (2003) · PubMed · Cited by 49
Long-Term Adjuvant Interferon Treatment of Human Osteosarcoma: A pilot study
Strander, H. A., Bauer, H. C. F., Brosjö, O., Fernberg, J.-O., Andris Kreicbergs, A., Nilsonne, U., Silfverswärd, C., Signomklao, T., & Söderlund, V. (1995) · Acta Oncologica · doi:10.3109/02841869509127199 · Cited by 45
Mossé, Y. P., Balis, F. M., Lim, M. S., Laliberté, J., Voss, S. D., Fox, E., Bagatell, R., Weigel, B. J., Adamson, P. C., Ingle, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.9500 · Cited by 43
A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma
Duffaud, F., Egerer, G., Ferrari, S. M., Rassam, H., Boecker, U., & Bui-Nguyen, B. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.015 · Cited by 33
Berger, M., Grignani, G., Giostra, A., Ferrari, S. M., Ferraresi, V., Tamburini, A., Cefalo, G., Carnevale‐Schianca, F., Vassallo, E., Picci, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr542 · Cited by 29
Impairment of Methotrexate Transport Is Common in Osteosarcoma Tumor Samples
Sowers, R. S., Wenzel, B. D., Richardson, C., Meyers, P. A., Healey, J. H., Levy, A. S., & Gorlick, R. G. (2010) · Sarcoma · doi:10.1155/2011/834170 · Cited by 26
Self-citationThimmaiah, K. N., Easton, J. B., & Houghton, P. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3693 · Cited by 18
Sulzbacher, I., Birner, P., Dominkus, M., et al. (2010) · Pathology · doi:10.3109/00313025.2010.520310 · Cited by 17
Bodmer, N., Walters, D. K., & Fuchs, B. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21236 · Cited by 14
Cited by
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 298
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
MiR-23a Functions as a Tumor Suppressor in Osteosarcoma
He, Y., Meng, C., Shao, Z., Wang, H., & Yang, S. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000366353 · Cited by 76
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1147-6 · Cited by 75
Metadata
- Authors
- Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 137
- Issue
- 1
- Pages
- 89-99
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1992018116
- Cited by
- 273
- References
- 101
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.